Professor Dyfrig Hughes
Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil
- 2009
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2009, 2009 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2009, 2009 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Tacrolimus (Advagraf) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2009, 2009 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Assessment, Determinants & Economics of Medication Compliance & Persistence Forum.
Hughes, D., Hughes, D. A., Gwadry-Sridhar, F. & Manias, E., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Comparisons between the medication possession ratio (MPR) and gaps measures of medication compliance: are we selling ourselves short by relying on the MPR?
Hughes, D., Nichol, M., Manias, E., Hughes, D. A. & Schabert, V. F., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Drug evaluation and pharmocoeconomics.
Hughes, D., Krska, J., Hughes, D. A., Winfield, A. J. (Golygydd), Rees, J. A. (Golygydd) & Smith, I. (Golygydd), 1 Ion 2009, Pharmaceutical Practice: 4th Edition.. 2009 gol. Churchill Livingstone, t. 185-198Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod
- Cyhoeddwyd
Economic evaluation of infliximab and adalimumab for Crohn's disease.
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Engaging with the MRC Methodology Hubs – NWHTMR.
Hughes, D. & Hughes, D. A., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.
Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Impact of the abolition of the prescription charge in Wales.
Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Impact of the abolition of the prescription charge in Wales.
Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Impact of the abolition of the prescription charge in Wales.
Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009, t. O41.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
The economics of evergreening.
Hughes, D. & Hughes, D. A., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- 2008
- Cyhoeddwyd
Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens
Hughes, D. & Hughes, D. A., 1 Rhag 2008, Yn: British Journal of Clinical Pharmacology. 65, 6, t. 871-878Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Impact of the abolition of the prescription charge in Wales
Hughes, D. & Hughes, D. A., 1 Tach 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Methodological Issues in the literature on costs of non-compliance in chronic diseases.
Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008, Yn: Value in Health. 11, 6, t. A571-A572Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Methodological issues in the literature on costs of non-compliance in chronic diseases
Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
The all wales medicines strategy group: assessments and appraisals
Hughes, D. & Hughes, D. A., 1 Tach 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Medicines concordance and game theory.
Hughes, D. & Hughes, D. A., 1 Hyd 2008, Yn: British Journal of Clinical Pharmacology. 66, 4, t. 577Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Economic considerations for pharmacogenetic testing
Hughes, D. & Hughes, D. A., 1 Meh 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Costs of non-compliance to antipsychotic medications among patients with schizophrenia.
Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Mai 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Mai 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Effects of the abolition of prescription charges in Wales: A preliminary analysis
Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Ebr 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment
Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Maw 2008Allbwn ymchwil: Ffurf annhestunol › Safe Gwe / Cyhoeddiad Gwe
- Cyhoeddwyd
Statistical comments are unfounded.
Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Maw 2008, Yn: Value in Health. 11, 2, t. 346Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data
Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Maw 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing
Hughes, D. & Hughes, D. A., 1 Chwef 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
From efficacy to cost-effectiveness: Impact of patient compliance
Hughes, D. & Hughes, D. A., 1 Chwef 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn